Evidence map›Paper›PMID 40533206›Full record

ArticleBMJ open2025

Global therapeutic mobilities and cancer: a scoping review.

Clémence Schantz, Sarah Boisson, Léa Prost-Lançon, Emmanuel Bonnet, Aurélien Dancoisne, Myriam Baron, Audrey Bochaton, SENOVIE Group

Abstract readScoping Review
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Clémence SchantzCentre Population et Développement (Ceped), Université Paris Cité, Institut de Recherche pour le Développement, Université Sorbonne Paris Nord, Inserm, Paris, France clemence.schantz@ird.fr.ORCID http://orcid.org/0000-0003-2825-4531
Sarah BoissonCentre Population et Développement (Ceped), Université Paris Cité, Institut de Recherche pour le Développement, Université Sorbonne Paris Nord, Inserm, Paris, France.
Léa Prost-LançonUniversité Paris Est Créteil, Lab'URBA, F - 94010, Créteil Cedex, France.
Emmanuel BonnetIRD, UMR 215 Prodig, 5, cours des Humanités, F-93 322, Aubervilliers Cedex, France.
Aurélien DancoisneOrthoweb, Bois-Colombes, France.
Myriam BaronUniversité Paris Est Créteil, Lab'URBA, F - 94010, Créteil Cedex, France.
Audrey BochatonUniversité Paris Nanterre-UMR 7533 Ladyss, Nanterre, France.
SENOVIE Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionResearch on therapeutic mobility is abundant but the field of cancer has not yet been investigated thoroughly. This scoping review aims to examine the existing evidence on global therapeutic mobility and cancer, providing a comprehensive overview of the subject.

methodsWe conducted a scoping review and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses methodological guidelines. We developed a comprehensive search strategy and discussed it with the research team. We searched for peer-reviewed papers on Medline, Embase, ERIC and American Psychological Association via the Dialogue interface and Google Scholar and CAIRN bibliographic database for peer-reviewed articles. We also included grey literature, such as unpublished work and relevant reports from Érudit. We considered studies that employed quantitative or qualitative methods.

resultsAmong the 1615 references initially selected, 767 duplicates were excluded. Then, 849 studies were screened on title and abstract and 800 were excluded as they did not meet inclusion criteria. 49 studies were fully screened and 21 were excluded as they did not meet inclusion criteria based on full-text assessment. Ultimately, 28 references were included in the data synthesis. This scoping review has shown that publications on therapeutic mobilities have multiplied in recent years, with a turning point in 2019. A range of academic disciplines and research methodologies are currently employed to describe them. A significant proportion of fieldwork is concentrated in Asia, Africa, Europe and North America. Despite the heterogeneity of the approaches and fields, there are certain common features that emerge: first, the decision to migrate for healthcare is primarily made by the patient themselves and is perceived by them as being non-choice; second, the family plays a central role at all stages of the migration; and third, the migration has a catastrophic impact in terms of social and financial burden.

conclusionIn conclusion, this scoping review highlights the underexplored relationship between global therapeutic mobility and cancer, emphasising the need for increased research efforts to understand the global dynamics of cancer care mobility.

Indexed as

Global HealthNeoplasmsHumansHealthHealth ServicesHealth Services AccessibilityONCOLOGYSystematic Review

Identifiers

PMID40533206
PMCPMC12182002

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.